Gary Berman, MD
Clinical & Laboratory Immunology · Minneapolis, MNNPI 1609836121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,791 of the $241,405 with a category attached, or 70.7%. 20 manufacturers reported payments, led by Lilly USA, LLC at 37.1% of the total. Reporting peaked in 2019 at $111,618 and has fallen 99.9% since, to $88 in 2025.
Across 350 payments — averaging $689.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$90K
- Amgen$69K
- Teva Pharmaceuticals USA, Inc.$35K
- Pfizer$18K
- AbbVie$14K
- Lundbeck LLC$6K
- plus $10K from 14 others
Across 2,836 payments — averaging $8508.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$21.5M
- AbbVie$706K
- Teva Pharmaceuticals USA, Inc.$283K
- Amgen$258K
- Siemens Medical Solutions USA, Inc.$257K
- H. Lundbeck A S$234K
- plus $866K from 13 others
What the payments were for
- Consulting fees$32,54213%
- Speaking & faculty fees$170,79171%
- Grants$850%
- Travel & lodging$32,65314%
- Food & beverage$5,3172%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 107 | $89,562 |
| Amgen | 103 | $69,065 |
| Teva Pharmaceuticals USA, Inc. | 25 | $34,642 |
| Pfizer | 15 | $18,046 |
| AbbVie(2 entities) | 28 | $14,316 |
| Lundbeck LLC | 15 | $5,682 |
| Modernatx, Inc. | 21 | $4,410 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $3,075 |
| Alk-abello, Inc | 13 | $1,317 |
| Eli Lilly | 1 | $700 |
| Novartis | 6 | $365 |
| GSK | 3 | $55 |
| Sanofi | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $29 |
| AstraZeneca | 2 | $26 |
| Aerin Medical Inc. | 1 | $20 |
| CSL Behring | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMGALITY$76,345
- AIMOVIG$67,298
- AJOVY$34,525
- NURTEC ODT$15,317
- UBRELVY$13,531
- VYEPTI$5,219
- ZAVZPRET$3,960
- Dust mite (D. farinae)$977
- BOTOX$375
How this compares
Too few clinical & laboratory immunology providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $63,474 |
| Breo ElliptaFluticasone/Vilanterol | 111 | $56,366 |
| Zileuton ErZileuton | 12 | $56,049 |
| Dupixent PenDupilumab | 14 | $53,097 |
| XolairOmalizumab | 28 | $51,884 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 21 | $39,975 |
| Advair HfaFluticasone Propion/Salmeterol | 50 | $29,213 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $24,329 |
| DuleraMometasone/Formoterol | 30 | $19,525 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,303 |
| Wixela InhubFluticasone Propion/Salmeterol | 50 | $12,364 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $11,199 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,612 |
| Arnuity ElliptaFluticasone Furoate | 29 | $8,350 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $55 | $128,190212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $26 | $27,15250 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $34,642 | $4,48915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical & laboratory immunology providers in Minnesotaon file to place this against a meaningful peer group, so we don't.
Other clinical & laboratory immunology in Minneapolis
- Hemalini MehtaMinneapolis$52K
- Richard BransfordMinneapolis$2K
- Philip HalversonMinneapolis$1K
- Allan StillermanMinneapolis$50
- Harold KaiserMinneapolis$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.